Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: A prospective analysis

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2029-2035

  Heemskerk Gerritsen, B A M ^a   Menke Pluijmers, M B E ^a,b   Jager, A ^a   Tilanus Linthorst, M M A ^a   Koppert, L B ^a   Obdeijn, I M A ^a   van Deurzen, C H M ^a   Collee J M ^a   Seynaeve, C ^a   Hooning, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

Bilateral risk reducing mastectomy; BRCA; Breast cancer; Surveillance; Survival

Indexed keywords

ADULT; ARTICLE; BILATERAL RISK REDUCING MASTECTOMY; BREAST CANCER; BREAST METASTASIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; TUMOR SUPPRESSOR GENE;

BILATERAL RISK-REDUCING MASTECTOMY; BRCA; BREAST CANCER; SURVEILLANCE; SURVIVAL;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MASTECTOMY; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; SURVIVAL;

EID: 84881255242     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt134     Document Type: Article

References (22)

1. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. Bergfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet 2002; 360: 891-894.
4. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
5. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87.
6. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
7. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-1637.
8. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
9. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-975.
10. Skytte AB, Crüger D, Gerster M, et al. Breast cancer after bilateral risk-reducing mastectomy. Clin Genet 2011; 79: 431-437.
11. Klaren HM, van 't Veer LJ, Van Leeuwen FE et al. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003; 95: 941-947.
12. Schrag D, Kuntz KM, Garber JE et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336: 1465-1471.
13. Grann VR, Jacobson JS, Thomason D, et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 2002; 20: 2520-2529.
14. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010; 28: 222-231.
15. Grann V, Patel P, Jacobson J, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 2011; 125: 837-847.
16. Kurian AW, Munoz DF, Rust P, et al. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 2012; 30: 497-506.
17. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
18. Leach M, Boggis C, Dixon A, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-1778.
19. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29: 1664-1669.
20. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012; 107: 24-30.
21. Rijnsburger AJ, Obdeijn I-M, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010; 28: 5265-5271.
22. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.